Kits Eyecare estimates Q1 revenue of $57.4M
“Pre‑Q1 revenue miss nudges growth outlook into focus as stock slides toward support”
- On 2026‑04‑07 Kits Eyecare released a preliminary Q1 2026 revenue estimate of $57.4 million.
- This figure is ~2–3 million below the company’s own guidance range of $58‑$60 million issued on 2026‑02‑17.
- The release notes a 23% YoY increase in total revenue and a 61% YoY jump in glasses revenue, with adjusted EBITDA now above 6% of revenue and cash balances at ≈$18.9 M.
- No new guidance revisions or operational updates were provided; the full audited results are slated for early May 2026.
| Aspect | Expectation vs. Result | Impact |
|---|---|---|
| Revenue | Guidance $58‑$60 M → reported $57.4 M (≈‑2–3 %) | Slight negative – a miss on the low end of guidance, but still strong YoY growth. |
| Glasses segment | 61% YoY increase (consistent with prior trends) | In line; reinforces the segment’s momentum. |
| Adjusted EBITDA margin | >6% (above prior quarter) | Positive incremental improvement, offsets revenue miss modestly. |
| Cash position | $18.9 M (unchanged from prior release) | Neutral – ample liquidity remains. |
| Overall market reaction | Stock price fell to $15.55, testing recent support levels. | Materiality is limited; the miss is routine rather than a fundamental shift. |
Conclusion: The news represents a routine negative deviation—still solid growth but below internal guidance, prompting modest downside pressure.
Kits Eyecare Ltd. operates a vertically integrated, digital‑first vision‑care platform that sells prescription glasses, contact lenses, and AI‑enabled “Pangolin” smart glasses. Flagship initiatives include:
- Glasses segment: Fast‑growing, high‑margin core business (61% YoY Q1 2026 growth).
- AI Smart Glasses (Pangolin): Gen‑3 launched Dec 2025; Gen‑4 slated for later 2026 with expanded camera/voice AI features.
- Retail expansion: Second flagship showroom in Toronto (Q1 2026) and plans for additional Canadian locations.